Is Rapport Therapeutics, Inc. Common Stock (RAPP) a Buy, Sell, or Hold?
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
$41.46 USD
$0.87 (2.14%)
- Volume
- 419.72K
- Average Volume
- 385.25K
- Market Capitalization
- $1.51B
- P/E Ratio
- -15.95
- Dividend Yield
- 0.00%
- Price Target
- $56.00
- Year High
- $43.76
- Year Low
- $13.43
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $27.08
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Abraham N. Ceesay |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | RAPP |
| CUSIP | 75383L102 |
| CIK | 0002012593 |
| Web | https://www.rapportrx.com |
| Phone | +1 617 945 0548 |
| Currency | USD |
| Employees | 84 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 27.08 |
| Quick Ratio | 27.08 |
| Cash Ratio | 4.36 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 75.66 |
| Cash Flow | -1.71 |
| Price / Cash Flow | -18.75 |
| Price / Book | 4.15 |
Price Target and Rating
| Average Stock Price Forecast | $56.00 |
| High Stock Price Forecast | $66.00 |
| Low Stock Price Forecast | $43.00 |
| Forecast Upside/Downside | -25.96% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.86 |
| Trailing P/E Ratio | -15.95 |
| PEG Ratio | 0.99 |
| P/E Growth | 0.99 |
| Net Income | $-111.48M |
| Net Margin | -536.39% |
| Pretax Margin | -536.39% |
| Return on Equity | -24.79% |
| Return on Assets | -21.56% |
Financials Score
| AltmanZ Score | 33.50 |
| Piotroski Score | 3.00 |
| Working Capital | 466.8M |
| Total Assets | 497.6M |
| Ebit | -119.14M |
| Market Cap | 1.47B |
| Total Liabilities | 26.08M |
Poll Results
About Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP) Stock
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine recept ... or (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
2026-07-12 19:33:01
COO Cheryl Gault sold 10,000 shares on June 30, 2026, for a transaction value of ~$416,000, based on a weighted average price of $41.58 per share. This sale represented 6.2% of Gault's direct holdings, reducing her position from 159,914 to 149,914 shares.
2026-06-08 15:48:31
Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
2026-05-20 16:05:00
BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences. Jefferies Global Healthcare Conference (New York City) – fireside chat on Wednesday, June 3, 2026, at 8:45 am ET.
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
2026-05-07 09:51:16
Rapport Therapeutics, Inc. (RAPP) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.68 per share a year ago.
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
2026-05-07 07:00:00
Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12 RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026, ahead of previous 1H 2027 guidance RAP-219 Phase 3 program in FOS remains on track for initiation in the second quarter of 2026 Pipeline programs, including RAP-219 long-acting injectable formulation, RAP-219 in primary generalized tonic-clonic seizures, and α6β4 nAChR in chronic pain and migraine, continue to advance Strategic collaboration and license agreement entered into with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China across indications Ended the first quarter of 2026 with $476.8 million in cash, cash equivalents and short-term investments, excluding restricted cash, expected to fund operations into the second half of 2029 BOSTON and SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the quarter ending March 31, 2026, and provided a business update. “We entered 2026 with strong momentum across the RAP-219 development program, highlighted by compelling new follow-up Phase 2a data recently presented at AAN that further reinforces RAP-219's treatment effect in focal onset seizures and builds confidence as we enter our Phase 3 trials,” said Abraham N.
Modalités de mise à disposition du rapport financier annuel 2025
2026-04-30 15:11:00
MODALITES DE MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 La société AdVini annonce avoir mis à la disposition du public et déposé auprès de l'Autorité des Marchés Financiers son Rapport Financier Annuel 2025.Le Rapport Financier Annuel peut être consulté sur le site internet de la société à l'adresse www.advini.com/finance - rubrique Informations Réglementées. A PROPOS D'ADVINI Fondé en 1872, AdVini est un groupe viticole international, porté par une âme familiale, un actionnariat visionnaire et humaniste et un esprit d'entreprendre.
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
2026-04-30 11:45:00
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 Dijon, France le 30 avril 2026 (17h45 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), société pharmaceutique spécialisée en phase avancée de développement et d'enregistrement de ZEPIZURE®, sa solution d'urgence pour la gestion des crises d'épilepsie, annonce avoir mis à la disposition du public et déposé auprès de l'Autorité des Marchés Financiers son rapport financier annuel 2025. Le rapport financier annuel 2025 peut être consulté sur le site internet de la société.
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near
2026-04-27 15:57:56
This Boston-based biotech innovator in CNS disorders just reported significant insider selling amid a year of standout stock gains.
Frequently Asked Questions
-
What is the current Rapport Therapeutics, Inc. Common Stock (RAPP) stock price?
-
Rapport Therapeutics, Inc. Common Stock(NASDAQ:RAPP) stock price is $41.46 in the last trading session. During the trading session, RAPP stock reached the peak price of $43.76 while $13.43 was the lowest point it dropped to. The percentage change in RAPP stock occurred in the recent session was 2.14% while the dollar amount for the price change in RAPP stock was $0.87.
-
RAPP's industry and sector of operation?
-
The NASDAQ listed RAPP is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of RAPP?
-
David Bredt | Founder & Chief Scientific Officer
Jeffrey Sevigny | Chief Medical Officer
Steven Paul | Founder & Independent Chairman
Troy A. Ignelzi | Chief Financial Officer
Abraham N. Ceesay | Chief Executive Officer, President, Treasurer & Director -
How many employees does RAPP have?
-
Number of RAPP employees currently stands at 84. RAPP operates from 1325 Boylston Street, Boston, MA None, US.
-
Link for RAPP official website?
-
Official Website of RAPP is: https://www.rapportrx.com
-
How do I contact RAPP?
-
RAPP could be contacted at phone #+1 617 945 0548 and can also be accessed through its website. RAPP operates from 1325 Boylston Street, Boston, MA None, US.
-
How many shares of RAPP are traded daily?
-
The average number of RAPP shares traded daily for last 3 months was 385.25K.
-
What is the market cap of RAPP currently?
-
The market value of RAPP currently stands at $1.51B with its latest stock price at $41.46